Full-Time

Executive Director RayzeBio Market Access Strategy & Go-to-Market Lead

Posted on 5/16/2026

Deadline 6/6/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$251.1k - $304.3k/yr

+ Incentive cash + Stock opportunities

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Hybrid

Hybrid role with at least 50% on-site presence at the assigned facility.

Category
Business & Strategy (2)
,
Requirements
  • 15+ years of progressive leadership experience in pharmaceutical market access, pricing, HEOR, Patient Services, or related strategic roles in the biopharmaceutical industry
  • BA or other advanced business degree preferred; BA/BA required; Life sciences degree or equivalent desirable
  • 3+ years of experience in oncology market access strongly preferred
  • Experience in radiopharmaceutical therapy (RPT) or nuclear medicine oncology preferred, including familiarity with site-of-care reimbursement, specialized distribution logistics, and the unique operational requirements of radiopharmaceutical products
  • Strong business acumen and analytical capabilities
  • Proven track record of strategic leadership, planning, and operations management in complex therapeutic areas
  • Strong understanding of global payer systems, HTA processes, and value-based healthcare
  • Exceptional change leadership and executive communication, influence, and stakeholder management skills, with the ability to navigate complex, matrixed environments and influence at all levels
  • Experience leading direct and cross-functional teams, driving organizational change
  • Strategic agility and comfort with ambiguity
  • Collaborative leadership style with a focus on enabling others
  • Passion for improving patient access and shaping the future of healthcare
Responsibilities
  • Lead development of RayzeBio Market Access organization strategy and go-to-market launch requirements, inclusive of key capabilities, resources, and organizational operational design, ensuring alignment with R&D and commercial priorities, leveraging BMS resources and capabilities
  • Design strategies that address unique access hurdles related to radiopharmaceutical supply chains and specialized treatment center requirements
  • Develop site readiness and infrastructure access strategies for RayzeBio program(s)
  • Direct design of patient and provider journeys, developing and implementing strategic solutions that meet patient access needs
  • Lead pricing strategy development in partnership with BMS Global Pricing, inclusive of net pricing frameworks and reimbursement positioning
  • Guide HTA submissions and payer negotiations for radiopharmaceutical products
  • Coordinate with key decision makers and communicate decisions supporting go-to-market preparations, including strategy development, budget/resource planning, and new capability requirements
  • Build a highly functioning team of direct reports and matrix resources across BMS to support RayzeBio’s commercialization market access objectives
  • Ensure adherence to regulatory and corporate standards across all operations
  • Foster cross-functional teamwork in matrixed environments, building trust and shared accountability with colleagues and partners
  • Collaborate with functions such as Global Policy, HEOR, Medical Affairs, operational teams, etc. to ensure integrated strategic planning
  • Partner with HEOR to develop economic models and evidence-generation plans (e.g., budget impact, RWE), and close key payer evidence gaps
  • Embraces diversity of thought and experience, driving innovation through inclusive practices
  • Identify and prioritize capabilities and future needs for RayzeBio
  • Lead initiatives to enhance strategic thinking, data-driven decision-making, and external engagement capabilities
  • Drive long-range planning and capability-building initiatives specific to Market Access considerations
  • Lead a highly functioning team (direct and matrix) to deliver key strategic objectives, supporting talent development and succession planning
  • Monitor and respond to evolving reimbursement landscapes specific to nuclear medicine and oncology
  • Drive innovation in value demonstration and access strategy, including digital, real-world evidence, and value-based operational models
  • Engage with external stakeholders (e.g., payers, HTAs, industry groups) to shape the future of access and value
Desired Qualifications
  • BA or other advanced business degree preferred; BA/BA required; Life sciences degree or equivalent desirable
  • 3+ years of oncology market access strongly preferred
  • Experience in radiopharmaceutical therapy (RPT) or nuclear medicine oncology preferred, including familiarity with site-of-care reimbursement, specialized distribution logistics, and the unique operational requirements of radiopharmaceutical products

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Avidity partnership adds $2.3 billion milestone optionality in RNA therapeutics.
  • Hengrui collaboration brings 13 early-stage programs across oncology, hematology, and immunology.
  • Direct Eliquis channels broaden access and support retention among self-pay patients.

What critics are saying

  • Eliquis pricing concessions compress margins and train buyers toward cheaper alternatives.
  • Revlimid and other mature brands face continued patent and generic erosion.
  • BMS's heavy dependence on Eliquis and Opdivo concentrates revenue risk dangerously.

What makes Bristol Myers Squibb unique

  • BMS leads in oncology, immunology, and cardiovascular medicines worldwide.
  • Eliquis and Opdivo anchor revenue, reducing dependence on one franchise.
  • Sotyktu's 2026 psoriatic arthritis approvals expand the growth portfolio.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Bristol Myers Squibb who can refer or advise you

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.